Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Herbal cancer cure claims

This article was originally published in The Tan Sheet

Executive Summary

David Walker, d/b/a DLW Consulting, permanently barred from representing dietary supple-ments, devices as "effective in treating and curing cancer" or as making "surgery, chemotherapy and other conventional cancer treatments unnecessary" absent competent and reliable scientific evidence, according to stipulated judgment signed by Tacoma, Wash. federal judge Oct. 23. In case brought by FTC, Walker also is required to turn over to commission customers' names, addresses; judgment includes monetary penalty if Walker made "material misrepresentations or omissions" in his financial disclosure form. FTC sued Walker in March related to cancer claims for CWAT-Treatment: BioResonance Therapy, which included dietary supplements (1"The Tan Sheet" April 8, 2002, p. 14). 2FTC press release notes Walker was required to pay $229,000 in consumer restitution under companion case brought by Washington AG...

You may also be interested in...



Herbal Cancer Cure One Of 63 Scams Targeted By FTC Internet Initiative

FTC's heightened focus on Internet fraud is reflected in a spate of 63 law enforcement actions the commission filed targeting deceitful Internet claims and/or deceptive spam (unsolicited commercial email.

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094730

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel